Compare Bristol-Myers Squibb Co (BMY) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Godaddy Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.41 (market cap $116.30B), while Godaddy Inc trades at $91.57 (market cap $12.06B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.6× Godaddy Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| BMY | GDDY | |
|---|---|---|
Market Cap | $116.30B | $12.06B |
Sector | Health | Technology |
52-Week High | $62.37 | $169.40 |
52-Week Low | $42.60 | $75.07 |
Enterprise Value | $152.24B | $14.65B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GoDaddy (GDDY) trades at $90.86, up 2.18% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust fundamentals, including a 17.32% net income margin and a P/E of 14.4, while analyst consensus is a Buy with a $123 price target. However, recent news highlights a securities class action investigation, adding a layer of risk.
The outlook remains positive due to consistent earnings performance and solid cash flow, but investors should weigh the legal overhang and high debt levels against the stock's growth potential and attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
